Kornimate/medical-research-clean huggingface dataset:
cross-sectional survey on the use of tobacco products - london (uk)

Conditions: Tobacco Use

Summary: the main purpose of the research study is to estimate the prevalence of tobacco product use and describe the tobacco use patterns in adults in london, united kingdom. the study was prematurely terminated after the first annual survey and was not be repeated due to the impossibility to recruit sufficient participants to meet the target sample size in the iqos user sample.

the aim of the survey is to describe the current and past patterns of use of tobacco products in the general adult population of the greater london area and in adult iqos users registered in the iqos user database of philip morris limited (uk iqos user database), and explore their association with key independent variables. more specifically, the objectives are: 1. estimate the prevalence of current tobacco use status in the study population. 2. describe the past tobacco use status (cigarette, iqos and other innovative products, including e-cigarettes) in the study population (i.e. never-use, initiation, product use transition, cessation, re-initiation, and relapse). 3. explore the association between self-reported health status and use of tobacco products in the study population. 4. explore the association between patterns of iqos use including motivation to use, mis-use, satisfaction, and self-reported changes since switching to the product (in a number of domains where iqos may have potential benefits), and consumer's satisfaction in the population of iqos users in the greater london area registered in uk iqos user database.

Eligibility criteria:
inclusion criteria (all participants, including iqos users): * legally permitted to buy tobacco products in uk (≥18 years of age). * currently residing in the greater london area. * able to read, write and understand english. * consent to participate in the survey inclusion criteria (iqos users only): * has used more than 100 heets tobacco sticks in his or her lifetime. * is currently using iqos. * has access to the internet. * is not currently employed by philip morris international or any of its affiliates exclusion criteria: * not meeting the inclusion criteria

Keywords: tobacco use iqos
4scar-t therapy post cd19-targeted immunotherapy

Conditions: CD19 Negative B-cell Malignancies

Summary: this study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified t cells (4scar-t) targeting cd19-negative b-all that express alternative surface antigens such as cd22, cd10, cd20, cd38, and cd123, as many patients relapse after anti-cd19 immunotherapy. clinical response and optiminzation of a standardized lentiviral vector and cell production protocol will be investigated. this is a phase i/ii trial enrolling patients from multiple clinical centers.

anti-cd19 immunotherapy based on antibody conjugated drugs or cd19-car-t cells has demonstrated unprecedented positive response in relapsing/refractory b-cell acute lymphoblastic leukemia (r/r b-all). however, many patients still relapse and up to 30-50% of those relapses are characterized by the loss of cd19 surface antigen. patients with cd19-negative relapse usually have a poor prognosis. the mechanisms underlying cd19-negative relapses are not fully understood and it is important to develop solutions to supplement post-cd19 immunotherapies. potential markers for recurrent leukemic blasts in an emerging cd19-negative blast population include many known b-cell lineage antigens. to prevent further target escape and improve the therapeutic effects, the 4th generation car gene-modified t cells targeting cd22, cd10, cd20, cd38, or cd123 have been considered in post anti-cd19 treatment. this study aims to evaluate safety and efficacy of administrating one or multiple non-cd19 targeting car-t cells to patients with cd19-escaped b cell malignancies.

Eligibility criteria:
inclusion criteria: 1. age older than 6 months. 2. b cell malignancies relapsed after anti-cd19 immunotherapy. 3. malignant b cells expressing one or more of the following surface molecules: cd22/cd123/cd38/cd10/cd20. 4. the kps score over 80 points, and survival time is more than 1 month. 5. greater than hgb 80 g/l. 6. no contraindications to blood cell collection. exclusion criteria: 1. complications with other active diseases, and difficult to assess patient response. 2. bacterial, fungal, or viral infection unable to control. 3. living with hiv. 4. active hbv and hcv infection. 5. pregnant and nursing mothers. 6. under systemic steroid use within a week of the treatment. 7. judged difficult to cooporate for continued evaluation.

Keywords: 4s car-t cd22 4s car-t cd123 4s car-t cd38 4s car-t cd10 4s car-t cd20 cd19 negative b cell leukemiab-all
evaluation of hypertension management and cardiovascular adverse event prevention in patients with b-cell malignancies undergoing treatment with bruton tyrosine kinase inhibitors, the halt study

Conditions: Chronic Lymphocytic Leukemia; Hematopoietic and Lymphoid System Neoplasm; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia

Summary: this study evaluates the incidence and management of new and worsening high blood pressure in patients with b-cell cancers on btki treatment.

primary objectives: i. to prospectively define the incidence of new and/or worsening htn in patients with b-cell malignancies on btki. ii. to identify the hemodynamic changes associated with new and/or worsening htn in patients with b-cell malignancies on btki by impedance cardiography (icg) and thereby to define the optimal anti-hypertensive strategies. iii. to compare 1-year mace rates between patients with b cell malignancies on btki with new or worsening htn on optimal anti-htn strategies with patients who do not develop htn on btkis. outline: this is an observational study. patients attend hypertension clinic visits, undergo optional blood pressure monitoring, electrocardiograms, impedance cardiography testing and blood and urine sample collection and have medical records reviewed throughout study.

Eligibility criteria:
inclusion criteria: * patients with chronic lymphocytic leukemia (cll), mantle cell lymphoma (mcl), waldenstrom macroglobulinemia (wm), and marginal zone lymphoma (mzl), planned to begin bruton tyrosine kinase inhibitors (btki) treatment or who will start a new btki agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to mayo clinic for ongoing follow-up exclusion criteria: * patients with known central nervous system (cns) involvement of their b-cell malignancy
percutaneous ethanol injection for benign cystic thyroid nodules

Conditions: Thyroid Nodule

Summary: use of ethanol injection in treatment of cystic thyroid nodule

thyroid nodules are common discreet lesions in the parenchyma of thyroid gland which can either be palpated or made out during imaging like ultrasonography (usg).clinically palpable thyroid nodules have a prevalence of 4-7% in the general population . however, the prevalence increases to 20-76% when usg is used for detection. goiter and the associated thyroid nodules result in anxiety, cosmetic disfigurement, and rarely compressive symptoms necessitating surgical removal, a procedure inherently associated with risks and complications percutaneous sclerotherapy has been suggested to be an effective alternative, especially in patients with cystic nodules. simple cystic (purely cystic) constitutes 6-28% of all thyroid nodules, are usually benign, filled with cellular debris or blood, and are a result of degeneration or hemorrhage into a hyperplastic nodule. among the various compounds (sodium tetradocyl sulfate, hydroxypolyethoxydodecan, tetracycline, and ethanol) tried for sclerosis of cystic thyroid nodules, outcomes are best and most studied with ethanol. however, data on outcomes of percutaneous aspiration and ethanol injection (pei) in resolution of thyroid nodules is highly variable in different studies (success rate: 38-85%), which may be due to different populations studied and the heterogeneous nature of thyroid nodules evaluated.

Eligibility criteria:
inclusion criteria: 1. adult male or female patient with cystic thyroid nodule 2. presence of pressure symptoms or cosmetic problems 3. benign lesions confirmed by histopathological examination by fnac. 4. serum levels of thyroid hormone thyrotropin, within normal limits. exclusion criteria: 1. nodules showing malignant features(ie, speculated margin, markedly hypo echoic, micro- or macro calcifications) at us 2. solid thyroid nodule 3. mixed thyroid nodule(cystic with solid component)
study to evaluate the efficacy and safety of dwj1464 in patients with chronic liver disease

Conditions: Chronic Liver Disease

Summary: this study aims to assess the effect of dwj1464 on improvement of liver function in patients with chronic liver disease. patients with chronic liver disease aged 19 years or over will participate in the study. the study design is a multi-center double-blinded randomized placebo-controlled trial. the patients were diagnosed with chronic liver disease based on our criteria and were randomized to either the placebo or dwj1464 administration group. primary endpoint was the change of alt level after 8 weeks compared to the baseline. secondary endpoints included the change of alt level after 4 weeks, the change rate of alt level after 8 weeks and improvement of fatigue, compared to the baseline. the adverse effect of dwj1464 were also recorded.


Eligibility criteria:
inclusion criteria: * patients with chronic liver disease(presented with abnormal serum alt levels \>6 months and twice continuously or abnormal area of liver through medical imaging test within 6 months * abnormal serum alt levels at screening and baseline exclusion criteria: * subjects who have diseases that liver cirrhosis, liver cancer, renal dysfunction etc. * subjects who are taking medications or supplements related to chronic liver disease, fatigue.
post-authorization safety study in ckd subjects receiving hx575 i.v.

Conditions: Chronic Kidney Disease

Summary: cumulative follow-up with hx575 epoetin alfa to prospectively monitor the incidence of relevant drug-related adverse events and epo-related lack of efficacy among chronic kidney disease (ckd) subjects receiving hx575 epoetin alfa i.v.

this study was a multi-center, multinational, prospective, single-arm clinical study with a 6-month treatment period. the primary objective was to extend the safety database of patients with ckd who receive i.v. hx575 epoetin alfa treatment and to monitor the adverse event (ae) profile under post-approval conditions.

Eligibility criteria:
inclusion criteria: * ckd subjects with or without dialysis treatment * age over 18 years * subjects requiring i.v. esa treatment * subjects likely to remain on i.v. esa treatment for 6 months * provision of informed consent - exclusion criteria: * systemic immunosuppressive medication or any other drugs known to adversely affect the hemoglobin level * known primary lack of efficacy (loe), unexplained loss of effect to a recombinant erythropoietin product * history of prca or aplastic anemia * history of anti-erythropoietin antibodies * uncontrolled hypertension * pregnant woman or nursing mother * women of childbearing potential do not agree to maintain effective birth control during the study treatment period.

Keywords: ckd subjects with or without dialysis treatment
optimizing quality of life in women living with metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to develop and tailor an intervention program to improve the quality of life in women living with metastatic breast cancer. in the first phase of this study, we conducted patient focus groups to gather information about the unique challenges of living with mbc and what kinds of support women would like to receive in a tailored acceptance and commitment therapy (act) intervention. in the second phase of the study, we will conduct a three-arm randomized controlled trial to the tailored act intervention with both a cognitive behavioral stress management (cbsm) intervention and usual care. the cbsm and act intervention groups will meet with a trained facilitator and 8-9 other patients, once per week via videoconference for 90 minute sessions over the course of 8 weeks.


Eligibility criteria:
inclusion criteria: * patients must be diagnosed with metastatic (stage iv \[m1\]) female breast cancer, via physician diagnosis and confirmed through staff review of electronic medical record (i.e. imaging, surgical pathology reports, etc.). * patients must be comfortable speaking english for participation in group sessions. * patients must be age ≥ 18 years. * patients taking part in the 8 week online pilot trial must have a physician-anticipated life expectancy of \> 6 months. * patients must have the ability to understand, and the willingness to sign, a written informed consent prior to registration on study. exclusion criteria: * patients who have severe or impairing psychiatric illness/social situations that would limit compliance with study requirements are not eligible to enroll. * patients with early stage/non metastatic breast cancer (stages i-iii) are not eligible to enroll.

Keywords: metastatic female breast cancer acceptance and commitment therapy stress management ehealth
text message safety behavior fading for appearance concerns

Conditions: Body Dysmorphic Disorders; Social Anxiety Disorder; Eating Disorders

Summary: the current study aims to explore the efficacy of a text message based safety behavior fadinig intervention compared to an unhealthy behavior fading intervention for appearance concerns.

description: appearance-related safety behavior fading intervention procedures will follow methodology previously used in the cougle lab. the safety behavior fading intervention is designed to target a decrease or elimination of appearance-related safety behaviors. individuals randomly assigned to the safety behavior fading condition will receive instructions to decrease or eliminate their endorsed appearance-related safety behaviors. in addition, they will receive daily reminders via text message to decrease these behaviors, along with a safety behavior monitoring checklist in which the participant indicates the extent to which they decreased and/or eliminated each safety behavior over the previous day. individuals randomly assigned to the unhealthy behavior fading condition will receive instructions to decrease or eliminate unhealthy behaviors. they will also receive daily reminders via text message to decrease these behaviors, along with a safety behavior monitoring checklist in which the participant indicates the extent to which they decreased and/or eliminated each safety behavior over the previous day.

Eligibility criteria:
inclusion criteria: * elevated appearance concerns as defined by a score of 53 or higher on the saas * being female exclusion criteria: * being male * score of 52 or lower on the saas * currently receiving treatment (therapy, counseling, etc.) for anxiety, depression, eating disorder, or body image/appearance concerns * if applicable, unstable psychiatric medication usage any time over the past 4 weeks

Keywords: safety behaviors intervention text message appearance concerns
colloidal silver, treatment of covid-19

Conditions: SARS (Severe Acute Respiratory Syndrome)

Summary: noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases. silver nanoparticles (agnps) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities i

noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases. silver nanoparticles (agnps) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. highly infectious viral diseases such as severe acute respiratory (sars), middle east respiratory syndrome (mers) and coronavirus disease (covid-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy. the current covid-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) .

Eligibility criteria:
inclusion criteria: * inclusion of any patient, over the age of 18, consulting the sahloul emergencies, sousse for symptoms of covid -19 dating less than 10 days and having a positive covid-19 on the pcr test and typical scanner. exclusion criteria: * any pregnant or breastfeeding woman * patient with an expectation of survival of less than 24 hours * dyspnea leading to heart failure * hepatic insufficiency * chronic respiratory failure * renal failure, clearance \<20ml • min-1 • 1.73 • m-²

Keywords: colloidal silver treatment covid-19
metabolic abnormalities in children with epilepsy

Conditions: Generalized Epilepsy; Infantile Spasms; Metabolic Disease; Partial Epilepsy; Seizures

Summary: this study is designed to use positron emission tomography to measure brain energy use. positron emission tomography (pet) is a technique used to investigate the functional activity of the brain. the pet technique allows doctors to study the normal processes of the brain (central nervous system) of normal individuals and patients with neurologic illnesses without physical / structural damage to the brain. when a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). as the brain uses more fuel it produces more waste products, carbon dioxide and water. blood carries fuel to the brain and waste products away from the brain. as brain activity increases blood flow to and from the area of activity increases also. researchers can label a sugar with a small radioactive molecule called fdg (fluorodeoxyglucose). as areas of the brain use more sugar the pet scan will detect the fdg and show the areas of the brain that are active. by using this technique researchers hope to answer the following questions; 4. are changes in brain energy use (metabolism) present early in the course of epilepsy 5. do changes in brain metabolism match the severity of patient's seizures 6. do changes in metabolism occur over time or in response to drug therapy

we propose to study children with recent onset partial epilepsy, cryptogenic infantile spasms, and idiopathic lennox-gastaut syndrome with serial fdg-pet to elucidate the natural history and evolution of metabolic abnormalities associated with such epilepsies. the severity of the seizure disorder, and cognitive impairment, when present, will be correlated with the presence and extent of focal and global cerebral metabolic abnormalities.

Eligibility criteria:
inclusion criteria: patients with partial seizures, infantile spasms and lennox-gastaut syndrome will be selected. exclusion criteria: evidence of a structural lesion as cause for epilepsy. degenerative or metabolic disease. inability to comply with the protocol.

Keywords: positron tomography seizures epileptic focus electroencephalography metabolism glucose cerebral positron emission tomography lennox gastaut syndrome
medi2228 in subjects with relapsed/refractory multiple myeloma

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: the purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (dlts), and determine the maximum tolerated dose (mtd) or maximum administered dose (mad \[in the absence of establishing the mtd\]) for single agent medi2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory.


Eligibility criteria:
inclusion criteria: 1. subjects must be ≥ 18 years of age at the time of screening. 2. subjects must have a confirmed diagnosis of relapsed/refractory mm as per imwg criteria (rajkumar et al, 2014) and have exhausted standard of care regimens with proven clinical benefit, which include agents from the following anti myeloma therapies: pis, imids, and mabs and have measurable disease with at least one of the following criteria: 1. serum m-protein ≥ 0.5 g/dl 2. urine m-protein ≥ 200 mg/24 hours 3. serum free light chain (flc) assay: involved flc level ≥ 10 mg/dl provided serum flc ratio is abnormal. 3. subjects must either be ineligible for or post-autologous stem cell transplant. 4. eastern cooperative oncology group (ecog) performance status of 0 to 1. 5. adequate organ and marrow functions as determined per protocol-defined criteria. exclusion criteria any of the following would exclude the subject from participation in the study: target disease: 1. subjects who have previously received an autologous stem cell transplant if less than 90 days have elapsed from the time of transplant or the subject has not recovered from transplant associated toxicities prior to the first scheduled dose of medi2228 2. subjects who have previously received an allogeneic stem cell transplant 3. central nervous system (cns) involvement(including meningeal involvement) by mri or cerebrospinal fluid exam 4. known history of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (poems) syndrome, plasma cell leukemia, waldenstrom's macroglobulinemia, or amyloidosis medical history and concurrent diseases: 5. any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results

Keywords: multiple myeloma relapsed/refractory open-label